Haematologic toxicities with PARP inhibitors in cancer patients: an up‑to‑date meta‑analysis of 29 randomized controlled trials
Author:
Affiliation:
1. College of Environment and Resource Chongqing Technology and Business University Chongqing P.R.China
2. College of Pharmacy Southwest Minzu University Sichuan P.R.China
Publisher
Wiley
Subject
Pharmacology (medical),Pharmacology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/jcpt.13349
Reference41 articles.
1. Functions of PARylation in DNA Damage Repair Pathways
2. Olaparib as maintenance treatment for patients with platinum‐sensitive relapsed ovarian cancer;Ledermann JA;Ther Adv Med Oncol,2019
3. FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
4. Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer
Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer
5. Veliparib: a new therapeutic option in ovarian cancer?
Cited by 32 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Neurological toxicities with poly (ADP-ribose) polymerase inhibitors in cancer patients: a systematic review and meta-analysis;Journal of Chemotherapy;2024-08-23
2. New Horizons of Synthetic Lethality in Cancer: Current Development and Future Perspectives;Journal of Medicinal Chemistry;2024-07-02
3. Expert Consensus Recommendations on the Management of Treatment-emergent Adverse Events Among Men with Prostate Cancer Taking Poly-ADP Ribose Polymerase Inhibitor + Novel Hormonal Therapy Combination Therapy;European Urology Oncology;2024-06
4. Safety and hematological toxicities of PARP inhibitors in patients with cancer: a systematic review of randomized controlled trials and a pharmacovigilance analysis;Expert Review of Anticancer Therapy;2024-05-23
5. Channeling Nicotinamide Phosphoribosyltransferase (NAMPT) to Address Life and Death;Journal of Medicinal Chemistry;2024-04-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3